GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (XSGO:AMGN) » Definitions » Operating Cash Flow per Share

Amgen (XSGO:AMGN) Operating Cash Flow per Share : $15.76 (TTM As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Amgen Operating Cash Flow per Share?

Amgen's operating cash flow per share for the three months ended in Dec. 2023 was $1.00. Amgen's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $15.76.

During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Amgen was -12.40% per year. During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -4.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 0.20% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Amgen's Operating Cash Flow per Share or its related term are showing as below:

XSGO:AMGN' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -4   Med: 13.3   Max: 239.8
Current: -4

During the past 13 years, Amgen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 239.80% per year. The lowest was -4.00% per year. And the median was 13.30% per year.

XSGO:AMGN's 3-Year OCF Growth Rate is ranked worse than
66.38% of 806 companies
in the Drug Manufacturers industry
Industry Median: 8.1 vs XSGO:AMGN: -4.00

Amgen Operating Cash Flow per Share Historical Data

The historical data trend for Amgen's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Operating Cash Flow per Share Chart

Amgen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Operating Cash Flow per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.03 17.79 16.16 17.97 15.75

Amgen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Operating Cash Flow per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.92 1.98 7.65 5.13 1.00

Competitive Comparison of Amgen's Operating Cash Flow per Share

For the Drug Manufacturers - General subindustry, Amgen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amgen's Price-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amgen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Amgen's Price-to-Operating-Cash-Flow falls into.



Amgen Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Amgen's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )=Cash Flow from Operations (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=8471/538.000
=15.75

Amgen's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )=Cash Flow from Operations (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=538/538.000
=1.00

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $15.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Amgen Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Amgen's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Amgen (XSGO:AMGN) Business Description

Industry
Address
One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen (XSGO:AMGN) Headlines

From GuruFocus

Amgen Inc at Citi BioPharma Conference Transcript

By GuruFocus Research 01-22-2024

Q2 2023 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc ESMO Call Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Evercore ISI HealthCONx Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc To Acquire Horizon Therapeutics Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Amgen Inc at Citi Global Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Amgen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024